1.Visualization analysis on research literature about Taohong Siwu Decoction based on CiteSpace
Shang LIU ; Yan CHEN ; Kanjana THANA ; Can WANG ; Ziqiong LONG ; Xingyue CHEN ; Xiaoxiao ZHANG ; Yitong HONG
International Journal of Traditional Chinese Medicine 2025;47(3):380-386
Objective:To understand the current research status, hot issues, and development trends of Taohong Siwu Decoction.Methods:Research literature about Taohong Siwu Decoction was retrieved from Wanfang Data, CBM, CNKI, and Chongqing VIP from January 1, 2014, to August 13, 2024. Excel 2024 software was used to analyze the annual number of publications, the source journals, literature types and the distribution of diseases and syndromes. CiteSpace 6.3.R3 software was used for visualization analysis on the authors, research institutions and key words.Results:A total of 2 519 articles were included, and the annual publication volume showed a fluctuating growth trend. There were 396 source journals, of which Medicine and Health published the most (80 articles); 208 authors were involved, and the core authors included Peng Daiyin of Anhui University of Chinese Medicine, Zhu Fuping of the First Affiliated Hospital of Hunan University of Chinese Medicine, Sun Shaoqiu of the Second Affiliated Hospital of Hunan University of Chinese Medicine and so on. The main research institutions in this field included Hunan University of Chinese Medicine and its affiliated hospitals. The high-frequency keywords included fracture, irregular menstruation, clinical efficacy, chloasma, Wuling Powder, experience of famous doctors, elderly, etc. Keywords could be clustered into 11 modules.Conclusions:The current research hotspots of Taohong Siwu Decoction mainly focus on the exploration of multi-system disease treatment, individualized syndrome differentiation and treatment, pharmacology and metabolic mechanism of Chinese materia medica, etc. Among them, the in-depth study of drug composition and metabolism, network pharmacology and mechanism is the research frontier in this field.
2.HDAC3:a new target for atherosclerosis therapy
Zihan XIA ; He ZHANG ; Ziqiong ZHANG ; Xingyi LI ; Yining WANG ; Weirong WANG
Chinese Journal of Arteriosclerosis 2024;32(7):621-626,640
Histone deacetylase 3(HDAC3)is an epigenetic modification enzyme,which participates in the occur-rence and development of atherosclerosis(As).It is significant to search for effective HDAC3 inhibitors for the treatment of atherosclerosis.This article reviews the relationship between HDAC3 and atherosclerosis,the latest research progress of HDAC3 inhibitors,and the therapeutic effects of some traditional Chinese medicine on cardiovascular diseases by inhibi-ting HDAC3.It aims to provide new ideas for developing anti-atherosclerotic drugs targeting HDAC3.

Result Analysis
Print
Save
E-mail